Abstract
We report the development of a large subretinal hemorrhage 4 weeks after intravitreal bevacizumab in an 84-year-old male with 20/70 visual acuity caused by occult choroidal neovascularization from neovascular agerelated macular degeneration in one eye that was treated with 1.25 mg of intravitreal bevacizumab.
Similar content being viewed by others
References
Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.
Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363–372.
Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495–511.
Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383–390.
Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumb for the management of choroidal neovascularization in age-related macular degeneration. Am J Opthalmol 2006;142:1–9.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE Dr. Fekrat has stated that he has a consultant relationship with Genentech Inc., manufacturer of a drug discussed in this article. The authors also discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products.
Rights and permissions
About this article
Cite this article
Chieh, J.J., Fekrat, S. Large subretinal hemorrhage after intravitreal bevacizumab (Avastin®) for age-related macular degeneration. Ann Ophthalmol 39, 51–52 (2007). https://doi.org/10.1007/BF02697326
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02697326